Borate Buffered Saline (pH 8.4 ± 0.2)

Human, baboon, bovine, chicken, guinea pig, hamster, horse.

≤ 30 Days 2-8˚C 

> 30 Days ≤ –20˚C

 For Research Use Only. Not for use in diagnostic procedures

The specificity of the monoclonal antibody for immobilized C9 was established by ELISA and radioimmunoassay (RIA). Subsequent experiments established that the antibody will immunoprecipitate highly purified, radiolabeled C9 protein. This antibody does not bind C9 determinants exposed in the assembled MAC deposited on cell membranes. It does not inhibit the lysis of antibody-coated sheep erythrocytes in an assay designed to measure specific C9 hemolytic activity. 

Complement protein, C9 is a single-chain glycoprotein with a molecular weight of 71 kD. The C9 protein is present in serum at a concentration of approximately 55 μg/ml. Upon activation of the Classical, Lectin or Alternative Complement Pathways, C9 becomes integrated into the Terminal Complement Complex (TCC). 

The Terminal Complement Complex (TCC) is the general term for both membrane bound C5b-9 (or Membrane Attack Complex; MAC) and fluid phase SC5b-9. Assessment of the TCC is an excellent marker for qualifying the extent of Terminal Pathway activation in vivo or in vitro. TCC can be deposited on the surface of transformed cells, biomaterials, and a variety of other surfaces.  

1、Barbashov, S., Wang C., Nicholson-Weller, A. Serum amyloid P component forms a stable complex with human C5b-6, J. Immunol. 158:3830-3835, 1997.

2、Verhuis, R., van der Valk, P. Complement activation in amyloid plaques in Alzheimer's Disease does not proceed further than C3, Virchos Arch 426:603-610, 1995.